Sam L. Barker is Director at LEXICON PHARMACEUTICALS, INC./DE (LXRX). They have made 11 open-market trades across 4 companies since 2008, most recently 2026-06-03.
CIK 0001226877
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
9 open-market purchases totalling $294K since 2008, against 2 sales. Across 6 scored buys the stock is up 23.6% at ninety days, and 20.6 points ahead of the S&P over the same stretch.
6 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 33% | 67% | 50% |
| Avg Move | -8.0% | -1.9% | +23.6% |
| Alpha | -5.0% | -2.4% | +20.6% |
| Scored | 6 | 6 | 6 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| CYCC | SELL | 2021-11-30 | 2021-12-02 | $3.57 | $43 | -1.2% | +30.9% | +0.6% |
| CYCC | BUY | 2021-08-24 | 2021-08-25 | $5.00 | $5K | +12.3% | +5.5% | -26.6% |
| LXRX | BUY | 2019-08-02 | 2019-08-02 | $1.18 | $28K | +16.0% | +3.2% | +196.8% |
| LXRX | BUY | 2017-09-15 | 2017-09-18 | $12.50 | $13K | -3.5% | -12.6% | -21.0% |
| CYCC | BUY | 2014-11-20 | 2014-11-20 | $3.00 | $9K | -30.8% | -8.9% | -8.9% |
| CADX | BUY | 2011-05-10 | 2011-05-11 | $7.04 | $63K | N/A | N/A | N/A |
| LXRX | BUY | 2009-10-22 | 2009-10-26 | $1.56 | $30K | -21.0% | +0.6% | +0.6% |
| AGIX | SELL | 2009-02-04 | 2009-02-05 | $0.04 | $1K | N/A | N/A | N/A |
| LXRX | BUY | 2008-04-18 | 2008-04-22 | $1.96 | $79K | -21.0% | +0.6% | +0.6% |
| CADX | BUY | 2008-03-17 | 2008-03-19 | $5.25 | $58K | N/A | N/A | N/A |
| AGIX | BUY | 2008-01-25 | 2008-02-01 | $0.39 | $10K | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.